KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (2016 - 2025)

Sarepta Therapeutics has reported Shares Outstanding over the past 15 years, most recently at $105.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $105.6 million for Q4 2025, up 8.99% from a year ago — trailing twelve months through Dec 2025 was $105.6 million (up 8.99% YoY), and the annual figure for FY2025 was $105.6 million, up 8.99%.
  • Shares Outstanding for Q4 2025 was $105.6 million at Sarepta Therapeutics, roughly flat from $105.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding for SRPT hit a ceiling of $105.6 million in Q4 2025 and a floor of $79748.0 in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $87.9 million (2022), compared with a mean of $61.7 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 99.9% in 2021 and later skyrocketed 109663.75% in 2022.
  • Sarepta Therapeutics' Shares Outstanding stood at $87127.0 in 2021, then surged by 100844.6% to $88.0 million in 2022, then grew by 6.57% to $93.7 million in 2023, then grew by 3.38% to $96.9 million in 2024, then increased by 8.99% to $105.6 million in 2025.
  • The last three reported values for Shares Outstanding were $105.6 million (Q4 2025), $105.4 million (Q3 2025), and $98.4 million (Q2 2025) per Business Quant data.